Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients

Neurology® 2020;95:661. doi:10.1212/WNL.0000000000008927

In the article “Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients” by Plavina et al.,¹ there is an error in the “Monocyte/VCAM-1 binding” key of figure 3. “Natalizumab continued” should have been represented by a green line and gray square; “Natalizumab interrupted” should have been represented by a red line and black circle. The editorial office regrets the errors.

Figure 3 Functional activity of CD3+ T cells, CD19+ B cells, and monocytes from RESTORE patients

Reference

1. Plavina T, Muralidharan KK, Kuesters G, et al. Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients. *Neurology* 2017;89:1584–1593.

Neurology®

Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients

Neurology 2020;95:661 Published Online before print September 16, 2020
DOI 10.1212/WNL.00000000000008927

This information is current as of September 16, 2020

Updated Information & Services

including high resolution figures, can be found at:
<http://n.neurology.org/content/95/14/661.full>

References

This article cites 1 articles, 1 of which you can access for free at:
<http://n.neurology.org/content/95/14/661.full#ref-list-1>

Permissions & Licensing

Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
http://www.neurology.org/about/about_the_journal#permissions

Reprints

Information about ordering reprints can be found online:
<http://n.neurology.org/subscribers/advertise>

Neurology® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright © 2020 American Academy of Neurology. All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.